← Leaderboards
Michael Frank
Indiana Univ-Purdue Univ At Indianapolis
$0
Attributed
$0
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
NIH$0 · 2
By mechanism
M01$0 · 2
Top collaborators
No co-investigators on record.
Most similar at Indiana Univ-Purdue Univ At Indianapolis
Same institution · by research overlap
- Mitchell Goldman$10,867,864
- Joseph Wheat$0
- Kenneth H. Fife$1,137,888
- Homer L Twigg$9,155,869
- Patrick J Loehrer$17,498,162
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectHiv InfectionsCytomegalovirus RetinitisCd8 MoleculeClinical Trial Phase ICommunicable Disease DiagnosisCytomegalovirusEye Disorder ChemotherapyHuman Immunodeficiency VirusHuman MortalityHuman Therapy EvaluationLongitudinal Human StudyOpportunistic InfectionsPathologic ProcessVirus DnaAidsVirus RnaAids TherapyBlood ChemistryCd4 Molecule
Grant awards (14)
HUMAN IMMUNODEFICIENCY VIRUS AND CYTOMEGALOVIRUS VIRAL BURDEN$0
M01 · FY2002 · RR
ACTG379: DISCONTINUATION OF THERAPY FOR CYTOMEGALOVIRUS RETINITIS$0
M01 · FY2002 · RR
HUMAN IMMUNODEFICIENCY VIRUS AND CYTOMEGALOVIRUS VIRAL BURDEN$0
M01 · FY2001 · RR
ACTG379: DISCONTINUATION OF THERAPY FOR CYTOMEGALOVIRUS RETINITIS$0
M01 · FY2001 · RR
HUMAN IMMUNODEFICIENCY VIRUS AND CYTOMEGALOVIRUS VIRAL BURDEN$0
M01 · FY2000 · RR
ACTG379: DISCONTINUATION OF THERAPY FOR CYTOMEGALOVIRUS RETINITIS$0
M01 · FY2000 · RR
ACTG379: DISCONTINUATION OF THERAPY FOR CYTOMEGALOVIRUS RETINITIS$0
M01 · FY2000 · RR
HUMAN IMMUNODEFICIENCY VIRUS AND CYTOMEGALOVIRUS VIRAL BURDEN$0
M01 · FY2000 · RR
ACTG379: DISCONTINUATION OF THERAPY FOR CYTOMEGALOVIRUS RETINITIS$0
M01 · FY2000 · RR
ACTG379: DISCONTINUATION OF THERAPY FOR CYTOMEGALOVIRUS RETINITIS$0
M01 · FY2000 · RR
ACTG379: DISCONTINUATION OF THERAPY FOR CYTOMEGALOVIRUS RETINITIS$0
M01 · FY2000 · RR
HUMAN IMMUNODEFICIENCY VIRUS AND CYTOMEGALOVIRUS VIRAL BURDEN$0
M01 · FY2000 · RR
HUMAN IMMUNODEFICIENCY VIRUS AND CYTOMEGALOVIRUS VIRAL BURDEN$0
M01 · FY2000 · RR
HUMAN IMMUNODEFICIENCY VIRUS AND CYTOMEGALOVIRUS VIRAL BURDEN$0
M01 · FY2000 · RR